Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. Keeping that in mind, here are three profitable companies to steer clear of and a few better alternatives.
Akamai Technologies (AKAM)
Trailing 12-Month GAAP Operating Margin: 13.5%
With a massive distributed network spanning 4,100+ points of presence in nearly 130 countries, Akamai Technologies (NASDAQ: AKAM) provides a global distributed cloud platform that helps businesses deliver, secure, and optimize their digital experiences online.
Why Should You Sell AKAM?
- Offerings struggled to generate meaningful interest as its average billings growth of 4.6% over the last year did not impress
- Bad unit economics and steep infrastructure costs are reflected in its gross margin of 58.9%, one of the worst among software companies
- Customer acquisition costs take a while to recoup, making it difficult to justify sales and marketing investments that could increase revenue
At $115.74 per share, Akamai Technologies trades at 3.7x forward price-to-sales. To fully understand why you should be careful with AKAM, check out our full research report (it’s free).
UiPath (PATH)
Trailing 12-Month GAAP Operating Margin: 3.5%
Starting with robotic process automation (RPA) and evolving into a comprehensive automation powerhouse, UiPath (NYSE: PATH) provides an AI-powered business automation platform that enables organizations to create software robots that mimic human actions to streamline repetitive tasks and processes.
Why Are We Wary of PATH?
- Sales trends were unexciting over the last two years as its 11% annual growth was below the typical software company
- Products, pricing, or go-to-market strategy may need some adjustments as its 7.4% average billings growth over the last year was weak
- Estimated sales growth of 9.1% for the next 12 months implies demand will slow from its two-year trend
UiPath is trading at $10.43 per share, or 3.4x forward price-to-sales. If you’re considering PATH for your portfolio, see our FREE research report to learn more.
Lantheus (LNTH)
Trailing 12-Month GAAP Operating Margin: 20.2%
Pioneering the "Find, Fight and Follow" approach to disease management, Lantheus Holdings (NASDAQGM:LNTH) develops and commercializes radiopharmaceuticals and other imaging agents that help healthcare professionals detect, diagnose, and treat diseases.
Why Does LNTH Worry Us?
- Smaller revenue base of $1.54 billion means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Forecasted revenue decline of 6.3% for the upcoming 12 months implies demand will fall off a cliff
- Efficiency has decreased over the last two years as its adjusted operating margin fell by 10.1 percentage points
Lantheus’s stock price of $80.72 implies a valuation ratio of 15x forward P/E. Check out our free in-depth research report to learn more about why LNTH doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
